Hepatitis C Virus infections trends in Italy, 1996-2006 by Torre, Giuseppe La et al.
KOWSAR
Journal home page: www.HepatMon.com
* Corresponding author: Giuseppe La Torre, Department of Public Health 
and Infectious Diseases, Sapienza University of Rome, Regina Aldo Maro 
5, 00185 Rome, Italy. Tel: +39-49970388; ext: 06, Fax: + 39-49972473; ext: 06, 
E-mail: giuseppe.latorre@uniroma1.it
DOI: 10.5812/kowsar.1735143X.767
Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
Hepatitis C Virus Infection Trends in Italy, 1996–2006
 Giuseppe  La  Torre  1*,   Maria Rosaria Gualano 2,   Leda Semyonov 1,   Nicola Nicolotti 2,   Walter 
Ricciardi 2,   Antonio Boccia 1
1 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
2 Institutes of Hygiene, Catholic University of the Sacred Heart, Rome, Italy
ARTICLE INFO ABSTRACT
Article history:
Received: 24 Apr 2011
Revised: 07 Jun 2011
Accepted: 18 Aug 2011
Keywords:
 Hepatitis  C
 Infection
 Trend
 Italy
Article type:
Original Article
  Please cite this paper as: 
La Torre G, Gualano MR, Semyonov L, Nicolotti N, Ricciardi W, Boccia A. Hepatitis C Virus Infection Trends in Italy, 1996-2006. Hepat 
Mon. 2011; 11(11):895-900. DOI: 10.5812/kowsar.1735143X.767
 Implication for health policy/practice/research/medical education:
Behavioral changes are a leading factor in the decrease of HCV infections. Every eﬀort should be made with the aim to maintain low 
levels of HCV infection. More attention, in particular, needs to be placed to improve socio-economic condition and to sanitation 
during medical procedures, even for those performed at home.
  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
Background: The World Health Organization (WHO) estimates that about 180 million peo-
ple, 3% of the world population, are infected with the hepatitis C virus (HCV). In Italy, the 
prevalence in the general population is reported to be greater than 5% and 9% among 
households of HCV-positive patients. 
Objectives: The aim of this study was to estimate the trends of HCV infection in Italy in 
the period 1996–2006.
Materials and Methods: The formula ln (rate) = b × years was applied for logarithmic trans-
formation of the incidence rates to obtain time trends of HCV infection, using the join-
point regression program software version 3.3.1. Linear graphs representing trends and 
the annual percentage change (APC) were considered for each joinpoint. Time changes 
are expressed as expected annual percentage change (EAPC) with the respective 95% con-
ﬁdence intervals (CIs); signiﬁcance levels of time trends are also reported. The null hy-
pothesis was tested using a maximum of 3 changes in slope with an overall signiﬁcance 
level of 0.05 divided by the number of joinpoints in the ﬁnal model.
Results: Considering all age groups, the incidence rate decreased from 2.02 to 0.55 per 
100,000. The joinpoint analysis showed a statistically signiﬁcant decrease in the inci-
dence rates of HCV infection. No joinpoints were found in any age groups. Our data 
show that the incidence rates of HCV infections have considerably decreased in each age 
group throughout the studied period (1996–2006). 
Conclusions: This decreasing trend in HCV infections is, in part, attributable to behavio-
ral and social changes. Improved hygiene, use of precautions in medical settings, blood 
screening, and sexual educational campaigns seem to have contributed to reduce the 
transmission of infection during the last 10 years.
Hepat Mon.2011;11(11):895-900. DOI: 10.5812/kowsar.1735143X.767
1. Background
Hepatitis C virus (HCV) infection is a major public 
health problem and chronic liver disease secondary to 
HCV is a leading indication for liver transplantation (1). 
In fact, infection with HCV is generally asymptomatic 
and in less than half of the infection cases, hepatitis be-
comes chronic, progressing to cirrhosis or liver cancer (2, 896 HCV Trends in Italy La Torre G et al.
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3). The disease burden of hepatitis C is high. The World 
Health Organization (WHO) estimates that about 180 
million people, 3% of the world population, are infected 
with HCV; of these, 130 million are chronic HCV carriers. 
Three to four million people are newly infected each year 
(2). Disease prevalence is low (< 1%) in Australia, Canada, 
and Northern Europe; it is approximately 1% in coun-
tries of medium endemicity, such as the USA and most 
of Europe, and high (> 2%) in many countries in Africa, 
Latin America, and Central and Southeastern Asia. In 
these countries, the prevalence of HCV infection could 
increase to 10% (2). Currently, the majority of HCV infec-
tions occur among adults, and injection drug use was the 
most common risk factor (4).
At present, this infection is not eradicable, as a vacci-
nation against hepatitis C is not yet available. Acquisi-
tion of HCV infection typically involves the parenteral 
route (transfusions of blood or blood products from 
unscreened donors, injection drug use, or unsafe thera-
peutic injections), but HCV can also be transmitted by 
occupational injury (contaminated needles or sharp in-
struments), hemodialysis, and tattooing (5). Moreover, 
dental care was found to be associated with HCV sero-
positivity (6). In addition, at least 50% of all HCV-positive 
patients do not have a history of blood transfusion or 
exposure to any other parenteral risk factor (7). In fact, 
familiar clustering of HCV infection has been demon-
strated in epidemiological studies, but it is still contro-
versial whether HCV can be transmitted to partners or 
other household contacts through horizontal transmis-
sion (8, 9). Since the late 1980s, the incidence of acute 
hepatitis C has also declined. In particular, with regard 
to HCV cases associated with transfusion, this decrease 
could be attributed to the requirement for blood screen-
ing worldwide (4). 
However, it is estimated that mortality related to HCV 
infection (death from liver failure or hepatocellular car-
cinoma) will continue to increase over the next 2 decades 
(9). In Italy, the incidence of HCV has decreased from 5 
per 100,000 in 1985 to 1 per 100,000 in 1996 (10). Mariano 
et al. (11), using mathematical modeling in order to esti-
mate the HCV burden from 1950 to 2030, predicted that 
the number of individuals with HCV-related cirrhosis 
and HCV liver-related deaths will be halved by 2025.
2. Objectives
The aim of this study was to estimate the trends of 
HCV infection in Italy in the period 1996–2006 for the 
whole population, as well as for gender and diﬀerent age 
groups, using the joinpoint regression method.
3. Materials and Methods 
Incidence rates of HCV infection (per 100,000) were cal-
culated using data of cases of the integrated epidemio-
logical system for acute viral hepatitis in Italy (SEIEVA) 
of the Italian Ministry of Health (12) and population data 
from the Health for All Database of the Italian National 
Institute of Statistics (ISTAT) (13), for the period 1996–
2006. Data regarding incidence rates were stratiﬁed by 
gender and age groups (in years: 0–14; 15–24; 25–64; ≥ 
65). In Italy, a ministerial decree of December 15, 1990, 
states the mandatory registration of illnesses that could 
constitute an epidemiological risk. Since 1993, data on 
frequency of some infectious diseases (including HCV 
infections) were published by the Italian Ministry of 
Health in the Italian Epidemiology Bulletin (13). Data are 
shown by year and speciﬁc age group. ISTAT is a public 
and independent research organization that operates in 
continuous interaction with the academic and scientiﬁc 
communities. Since 1926, it is the main producer of oﬃ-
cial statistics in Italy, available for citizens, researchers, 
and policy-makers. Data on the resident population are 
extrapolated from the registry oﬃce records of Italian 
municipalities.
3.1. Statistical Analysis
Rates were computed as number of cases per general 
population, as previously described. In order to obtain 
time trends of HCV infection, the following formula (14) 
was applied for logarithmic transformation of incidence 
rates:
                                          ln (y) = b × x,
Where “x” represents the calendar years, “b” is the re-
gression coeﬃcient, and “y” the incidence rate. In par-
ticular, a joinpoint represents the time point when a 
signiﬁcant trend change is detected. Time changes are 
expressed as expected annual percentage change (EAPC) 
with the respective 95% conﬁdence interval (95% CI); sig-
niﬁcance levels of time trends are also reported. The null 
hypothesis was tested using a maximum of 3 changes in 
slope with an overall signiﬁcance level of 0.05 divided 
by the number of joinpoints in the ﬁnal model. Linear 
graphs were created to represent trends. Statistical anal-
ysis was conducted by using the joinpoint regression 
program software version 3.3.1. The Poisson model was 
applied to control heteroskedasticity in the population.
4. Results
A total number of 6,806 cases of HCV infection occurred 
during the period 1996–2006, and a strong reduction in 
the incidence rates of HCV infection was observed in all 
age groups (Figure 1). In particular, in 1996, the highest 
incidence rate of HCV infection was found in subjects 
aged from 15 to 24 years (2.97 per 100,000), followed by 
the 25–64 years age group (2.16 per 100,000). In the pe-
riod 1996–2006, the incidence rate decreased from 0.43 
to 0.10 per 100,000 in the age group 0–14 years, from 2.97 
to 0.66 in the group 15–24 years, from 2.16 to 0.67 in the 
age group 25–64 years, and from 2.11 to 0.41 in subjects 
aged 65 years or older. Considering all age groups, the 
incidence rate decreased from 2.02 to 0.55 per 100,000.
Trend analysis showed a statistically signiﬁcant de-
crease in the incidence rates of HCV infection in all age 
groups. The most remarkable decrease was noted among 897 HCV Trends in Italy La Torre G et al.
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the male population. In this group, in the period 1996–
2006, the incidence rate decreased from 0.59 to 0.05 per 
100,000 in the age group 0–14 years, from 4.25 to 0.90 in 
the group 15–24 years, from 2.81 to 0.88 in the age group 
25–64 years, and from 2.64 to 0.45 in subjects aged 65 
years or older. However, in the female population for 
the same time period, the incidence rate changed from 
0.27 to 0.15 per 100,000 in the age group 0–14 years, from 
1.64 to 0.41 in the group 15–24 years, from 1.53 to 0.47 in 
the age group 25–64 years, and from 1.75 to 0.38 in sub-
jects aged 65 years or older. The EAPCs were -13.57 (95% CI: 
-18.92; -7.88) for the 0–14 age group; -13.57 (95% CI: -16.37; 
-10.67) for the 15–24 age group; -11.6 (95% CI: -12.93; -10.26) 
for the 25–64 age group; and -14.29 (95% CI: -17.14; -11.34) for 
subjects aged 65 years or older (Table 1). The overall an-
nual decrease was -12.45% (P < 0.001). No joinpoints were 
found in any age groups. Trend analyses by age group are 
shown in Figures 2-6.
5. Discussion
This study describes for the ﬁrst time the trend of HCV 
infections in Italy after 1996 using the joinpoint regres-
sion method. Our study shows that in Italy, incidence 
rates of HCV infection have considerably decreased in 
each age group throughout the studied period (1996–
2006). This trend is statistically signiﬁcant, particularly 
among young people. In most European countries, the 
prevalence of HCV infection ranges from 0.5% to 2% (15); 
whereas in Italy, a prevalence greater than 5% has been re-
ported in some communities (16). In addition, the preva-
lence of HCV infection is 9% among households of HCV-
positive patients (17). The strength of our study is that we 
EACP a, % 95% CI a P value
Male
0–14 -16,58 (-23.78; -8.69) < 0.01
15–24 -14,2 (-16.91; -11.31) < 0.001
25–64 -11,07 (-12.65; -9.46) < 0.001
≥ 65 -13,95 (-17.95; -9.75) < 0.001
All age groups -12,23 (-13.51; -10.93) < 0.001
Female
0–14 -7,78 (-14.29;  -0.77) 0.03
15–24  -11,68 (-16.42; -6.66) < 0.001
25–64  -12,62 (-14.71; -10.47) < 0.001
≥ 65 -14,67 (-18.12; -11.07) < 0.001
All age groups -12,8 (-14.86; -10.69) < 0.001
Total
0–14 -13,57 (-18.92; -7.88) < 0.001
15–24 -13,57 (-16.37; -10.67) < 0.001
25–64 -11,6 (-12.93; -10.26) < 0.001
≥ 65 -14,29 (-17.14; -11.34) < 0.001
All age groups -12,45 (-13.76; -11.12) < 0.001
Table 1. Results of the Joinpoint Regression Analysis by Age Group and Gender during the Period 1996–2006
a Abbreviations: CI, conﬁdence interval; EACP, estimated annual percentage change
Figure 1. Incidence Rates of Hepatitis C Virus (HCV) Infections per 
100,000 in Italy, 1996–2006 (Linear Scale)
Figure 2. Trend of Incidence Rates (per 100,000) of Hepatitis C Virus 
(HCV) Infections in Italy (Age: 0–14 Years), 1996–2006
APC = annual percentage change898 HCV Trends in Italy La Torre G et al.
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examined HCV infection trends among the general Ital-
ian population for a 10-year period. In addition, while the 
majority of studies have described the epidemiology of 
HCV among speciﬁc groups of people, i.e. blood donors, 
drug users and health care workers (18-34), only a few 
studies have described the prevalence of HCV infections 
considering the general population (35-42). The signiﬁ-
cant decrease in HCV infections underlines the behavior-
al changes that have taken place in recent years, and the 
special attention paid to sanitation during medical pro-
cedures, even for those performed at home. In fact, the 
current decrease in the incidence of HCV infection may 
be attributable to several factors, i.e. improved socio-eco-
nomic conditions, smaller family size, introduction of 
compulsory screening for anti-HCV in blood banks, more 
Figure 3. Trend of Incidence Rates (per 100,000) of Hepatitis C Virus 
(HCV) Infections in Italy (Age: 15–24 Years), 1996–2006
APC = annual percentage change
APC = annual percentage change  APC = annual percentage change
APC = annual percentage change
Figure 5. Trend of Incidence Rates (per 100,000) of Hepatitis C Virus 
(HCV) Infections in Italy (Age: > 65 Years), 1996–2006
Figure 6. Trend of Incidence Rates (per 100,000) of Hepatitis C Virus 
(HCV) Infections in Italy (All Age Groups), 1996–2006
Figure 4. Trend of Incidence Rates (per 100,000) of Hepatitis C Virus 
(HCV) Infections in Italy (Age: 25–64 Years), 1996–2006
() y ( g )
sensitive procedures for HCV screening of blood dona-
tions and widespread use of disposable syringes (43). 
Some limitations of this study have to be acknowl-
edged. The estimates derived from the Health Informa-
tion System could be aﬀected by the open access to the 
health services and by the poor quality and irregularity 
of reporting. Therefore, data sources were critically as-
sessed to take into account the possibility of under- or 
overestimation and to ensure that the reports were con-
sistent with the epidemiological knowledge about dis-
eases. At present, the residual risk of HCV transmission 
by transfusion is very low in industrialized countries; 
newly diagnosed cases of HCV infection could be lim-
ited to marginal risk factors, i.e. nosocomial infections, 
vertical transmission and use of intravenous drugs and 899 HCV Trends in Italy La Torre G et al.
Hepat Mon. 2011;11(11):895-900
beauty treatments. This supports the hypothesis that the 
prevalence of HCV infection will decrease signiﬁcantly 
over the next 2 decades (44). Identiﬁcation of HCV-pos-
itive persons for appropriate counseling and manage-
ment is the major focus of a national prevention pro-
gram, and routine testing is recommended for persons 
likely to have an HCV infection (45). Since an active im-
munization against HCV is still not available, precaution 
in medical settings, blood screening, sexual educational 
campaigns  and hygiene campaigns for drug-addicts are 
the most powerful control measures necessary to reduce 
the prevalence of this infection, which represents a main 
goal of public health services. 
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